Compass Therapeutics Inc.
NASDAQ:CMPX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Compass Therapeutics Inc.
Cash & Cash Equivalents
Compass Therapeutics Inc.
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Compass Therapeutics Inc.
NASDAQ:CMPX
|
Cash & Cash Equivalents
$30.6m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash & Cash Equivalents
$5.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-5%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash & Cash Equivalents
$10.6B
|
CAGR 3-Years
25%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash & Cash Equivalents
$9.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash & Cash Equivalents
$6.6B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
2%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash & Cash Equivalents
$18.9B
|
CAGR 3-Years
82%
|
CAGR 5-Years
54%
|
CAGR 10-Years
37%
|
|
Compass Therapeutics Inc.
Glance View
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2020-11-13. Its pipeline of product candidates includes both angiogenesis-targeted agents and immune-oncology focused agents. These product candidates are designed for anti-tumor response to cancer. Its lead product candidate, CTX-471, is a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells. Its second product candidate, CTX-8371, is a bispecific antibody that simultaneously targets both PD-1 and PD-L1, the targets of checkpoint inhibitor antibodies. In addition to CTX-471 and CTX-8371, It is also developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. Its product candidate, CTX-009, is an anti-DLL4 x VEGF-A bispecific antibody, which has added to its pipeline through Trigr Therapeutics, Inc. (TRIGR).
See Also
What is Compass Therapeutics Inc.'s Cash & Cash Equivalents?
Cash & Cash Equivalents
30.6m
USD
Based on the financial report for Dec 31, 2025, Compass Therapeutics Inc.'s Cash & Cash Equivalents amounts to 30.6m USD.
What is Compass Therapeutics Inc.'s Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-8%
Over the last year, the Cash & Cash Equivalents growth was -30%. The average annual Cash & Cash Equivalents growth rates for Compass Therapeutics Inc. have been -4% over the past three years , -8% over the past five years .
